Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
24.09.2026 04:20
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines. InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
24.09.2026 04:20
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines. InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
23.09.2026 15:32
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
23.09.2026 14:11
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
23.09.2026 13:42
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?
23.09.2026 13:00
Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.
AutoZone (AZO) Posts Strong Earnings, But Is the Stock Ready to Rebound?
23.09.2026 12:41
On September 22, AutoZone, Inc. (NYSE:AZO) reported results for its fourth quarter, which covered 16 weeks and ended August 29, 2026. The company delivered stronger-than-expected profits and the stock ended the session 3.26% higher. The company’s net sales increased 5.6% year-over-year to $6.6 billion, while operating profit rose 10.1% to $1.3 billion. Net income reached […]
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
23.09.2026 12:41
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
23.09.2026 12:00
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipelineAX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development pro
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
23.09.2026 11:03
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
23.09.2026 11:00
Eli Lilly and Co.‘s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decision to cover obesity drugs. On Monday, Ricks said in an interview with CNBC that 70% of the...
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
23.09.2026 03:50
Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.
Obesity titan could shake up Lilly and Novo after astonishing trial
23.09.2026 02:31
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
23.09.2026 02:22
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
AlzeCure Pharma to Present at Swiss Nordic Bio 2026 in Zurich
22.09.2026 08:20
STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.At the event, CEO Martin
AlzeCure Pharma to Present at Swiss Nordic Bio 2026 in Zurich
22.09.2026 08:20
STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.At the event, CEO Martin
2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off
22.09.2026 07:33
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off
22.09.2026 07:33
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Sector Update: Healthcare Stocks Rise in Afternoon Trading
21.09.2026 17:50
Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index increasing 0.5% and the Stat
The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect
21.09.2026 17:30
Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.